Résumé
OBJECTIVE@#To evaluate the clinical value of inflammation-related markers in predicting the prognosis of patients with ureteral urothelial carcinoma.@*METHODS@#200 patients with ureteral urothelial carcinoma were randomly divided into two groups by split sample validation: modeling group and validation group. Paraffin embedded pathological specimens of the patients were reviewed. Immunohistochemical method was used to detect tumor-infiltrating neutrophil (TIN) (CD66b+), tumor-associated macrophage (TAM) (CD163+), lymphocyte (CD+, CD4+, CD8+) counts, peripheral blood neutrophil / lymphocyte ratio (NLR) and tumor tissue neutrophil/monocyte ratio (NMR). According to the results of pathological staging, the patients were divided into non-muscle-invasive and muscle-invasive ureteral urothelial carcinoma group. The resolution of the models was evaluated, and the prognostic nomogram models including only peripheral blood parameters and all parameters were established to compare the accuracy of the two models in predicting the prognosis of patients with urothelial carcinoma of the ureter.@*RESULTS@#The median follow-up time was 36 months, the progression-free survival was 40 months, and 42 cases (21.0%) showed tumor progression within 3 years. Tumor size, pathological stage and pathological grade were all single-factor variables predicting the first recurrence of ureteral urothelial carcinoma three years after operation. Tumor size, pathological stage, pathological grade, TIN, TAM, NLR and NMR were multi-factor variables predicting the first recurrence three years after operation. Among 104 cases of non-muscle-invasive ureteral urothelial carcinoma, 10 cases (9.6%) recurred for the first time 3 years after operation, 96 cases (33.3%) of muscle invasive ureteral urothelial carcinoma, and the diffe-rence between the two groups was statistically significant (χ2=15.53, P < 0.05). The predictive nomogram model of progression free survival was established. The concordance index of progression free survi-val was 0.722 (95%CI: 0.70-0.78) in non-muscle-invasion group, and 0.725 (95%CI: 0.71-0.79) in muscle-invasion group, which was in good agreement with the observed 3-year survival rate. The results of discrimination test showed that the concordance index of the whole parameter prediction model of ureteral urothelial carcinoma was 0.726, which was higher than that of peripheral blood parameters (consistency index 0.672). The immune microenvironment of ureteral urothelial carcinoma improved the prediction accuracy of the model.@*CONCLUSION@#The prognosis prediction model based on immune inflammation-related markers was established as a perfection and supplement for the existing pathological grading and staging system, providing a basis for accurate individualized treatment of patients with urete-ral urothelial carcinoma. The prognosis prediction model based on the relevant indicators of peripheral blood samples is established, which is easy to obtain specimens, and the detection method is simple and economical, which is more conducive to clinical application.
Sujets)
Humains , Marqueurs biologiques , Carcinome transitionnel/diagnostic , Récidive tumorale locale , Pronostic , Études rétrospectives , Microenvironnement tumoral , Tumeurs de l'uretère/diagnosticRésumé
Objective:To investigate the effects and mechanisms of long non-coding RNA UCA1 on cell survival and migration of bladder cancer cell UM-UC-3 by targeting miR-582-5p.Methods:Cells were transferred with UCA1 shRNA(sh-UCA1)and(or)miR-582-5p,the transfection efficiency and level of miR-582-5p were detected by RT-PCR.The luciferase report assay was performed for validate the relationship of UCA1 and miR-582-5p.The cell viability was measured by CCK8 assay.Apoptosis was detected by flow cy-tometry.The metastatic ability was calculated by wound healing and Transwell assay.And the protein levels of proliferation-,apoptosis-and migration-related were determined by Western blot.Results:sh-UCA1 inhibited the expression of UCA1 and induced the expression of miR-582-5p(P<0.05),and miR-582-5p inhibitor alleviated the effect of UCA1 on miR-582-5p(P<0.05).The luciferase reporter assay indicated that there was miR-582-5p binding site on UCA1.Silencing of UCA1 inhibited proliferation of bladder cancer cells and the expression of Ki67,induced apoptosis and expression of cleaved caspase-3(P<0.05).Meanwhile,sh-UCA1 inhibited migration and invasion of bladder cancer cells coupled with decreasing VEGF(P<0.05).In addition,miR-582-5p inhibitor attenuated the effects of UCA1 on proliferation,apoptosis and migration(P<0.05).Conclusion:UCA1 promotes survival and migration of bladder cancer cells through targeting miR-582-5p.
Résumé
<p><b>OBJECTIVE</b>To study the expressions of Integrinalpha2beta1 and CD133 in benign prostatic hyperplasia (BPH) complicated by prostatitis and their significance.</p><p><b>METHODS</b>Specimens were obtained from 56 BPH patients undergoing transvesical prostatectomy. Paraffin sections of the specimens were subjected to HE staining for pathological examination of inflammatory changes under the light microscope. Twenty-four patients with simple BPH were included in Group A, and the other 32 with BPH complicated with prostatitis in Group B. The expressions of Integrinalpha2beta1 and CD133 in the prostatic tissues of the two groups were determined by immunohistochemistry, Western blotting and IPP6.0 image analysis software.</p><p><b>RESULTS</b>The expressions of Integrinalpha2beta1 and CD133 were significantly higher in Group B than in A (P < 0.05), and so were the mean relative value of the optical density of Integrinalpha2beta1 (0.29 +/- 0.18 vs 0.04 +/- 0.03) and that of CD133 (0.08 +/- 0.07 vs 0.0020 +/- 0.0018) (P < 0.05).</p><p><b>CONCLUSION</b>Inflammation can up-regulate the expressions of Integrinalpha2beta1 and CD133 in BPH tissue.</p>